Email Address
Please enter your official email address
We notice that your permissions preference cookie is missing. Please enter your email address so we can determine if you need to complete a permission form or verify that you have already completed this form. Receiving permission from our users is an important part of our compliance with international privacy regulations. Your email address will not be shared without your permission. Please refer to our
privacy policy
for information on how we protect your personal information.
Welcome to AdisInsight
We need some information from you before you start using the platform.
This information will allow us to better understand how AdisInsight is being used.
It does not require or replace the individual login accounts that many of you use to save searches and create email alerts.
Protecting your personal information is important.
That is why AdisInsight collects the minimum amount of information necessary to enable functionality, report usage, and contact you with information about AdisInsight.
For further information on how we protect and process your personal information, please refer to our
privacy policy.
Terms of Service
By accessing or using the AdisInsight platform you agree to the terms of use.
Please select terms of use
How much you and your colleagues use AdisInsight often determines if your organization will continue paying to provide access to the platform.
The number of times you access AdisInsight, the number of searches you performed, and the number of profiles you viewed will be provided to your organization both in aggregate with other users and individually by your email address.
You have the right to opt-out of sharing your email address with your organization but doing so may negatively affect your organization’s decision to renew their subscription to AdisInsight. If you opt-out your email will still be collected for registration purposes.
Please choose your email permissions
Get more from AdisInsight
Keep up to date with all things AdisInsight by signing up to receive our product bulletin, which includes related content from Springer Nature such as white papers, product news, industry commentaries, and webinar invites, straight to your inbox. Unsubscription is always possible via email.
Adis is an information provider.
We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.
At a glance
Originator
EMD Serono; Merck KGaA
Developer
AIO Studien gGmbH; Array BioPharma; Chong Kun Dang; Dana-Farber Cancer Institute; Debiopharm; eFFECTOR Therapeutics; EMD Serono; Forty Seven; Fred Hutchinson Cancer Research Center; Gachon University Gil Medical Center; Hellenic Cooperative Oncology Group; Hoosier Cancer Research Network; Hospices Civils de Lyon; Istituto Oncologico Veneto; Johannes Gutenberg-University Mainz; M. D. Anderson Cancer Center; Merck KGaA; National Cancer Institute (USA); National Cancer Institute Slovakia; Netherlands Cancer Institute; Pfizer; Seoul National University Hospital; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Syndax Pharmaceuticals; Transgene; University College London; University of Birmingham; University of California, San Diego; University of Iowa; University of North Carolina at Chapel Hill; University of Padua; Vaccinex; Vanderbilt-Ingram Cancer Center; VAXIMM; Verastem Oncology; Washington University School of Medicine
Class
Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action
Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Yes
-
Merkel cell carcinoma
New Molecular Entity
Yes
Highest Development Phases
Marketed
Merkel cell carcinoma; Renal cell carcinoma; Urogenital cancer
Phase III
Breast cancer; Diffuse large B cell lymphoma; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
Phase I/II
Anal cancer; Bone metastases; Cervical cancer; Liposarcoma; Oropharyngeal cancer; Pancreatic cancer; Vulvovaginal cancer
Phase I
Acute myeloid leukaemia; Follicular lymphoma; Meningioma
Most Recent Events
19 May 2021
Updated efficacy data from Part A of the phase II JAVELIN Merkel 200 trial in Merkel cell carcinoma released by EMD Serono
06 May 2021
NICE does not recommend avelumab for maintenance treatment of advanced or metastatic Urogenital cancer after platinum-based chemotherapy in its draft guidance
03 May 2021
Pfizer and University of California, San Diego terminates a phase I/II clinical trial in Non-small cell lung cancer (Early-stage disease, Inoperable/Unresectable) in USA (IV) (NCT03050554)
Subscriber content
You need to be a logged in subscriber to view this content.
If your organization
has a subscription
then there are several options available to help you access AdisInsight, even while working remotely.
IP authentication when working within your organization’s network.
Login
with a username/password associated to your organization’s account.
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Federated access using single sign-on credentials.
If your organization
does not have a subscription
to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.
Contact your organization’s admin about adding this content to your AdisInsight subscription
